Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
BIO-TECHNE Corp director John L. Higgins exercised 15,940 stock options on September 28, 2026, at an exercise price of $25.30, acquiring 15,940 common shares. He also had 5,562 shares delivered or withheld for payment of exercise price or tax liability, at $72.51 per share. Remaining option holdings include 12,500 options at $31.26, expiring October 26, 2027, and 3,777 options at $60.96, expiring October 30, 2035.
BIO-TECHNE Corp (TECH) director Robert V. Baumgartner exercised options for 15,940 common shares on September 22, 2026, at a $25.30 exercise price. On the same date, 5,559 shares were delivered or withheld for payment of exercise price or tax liability, at a reported $72.55 per share. No Rule 10b5-1 plan is reported.
His listed remaining options include 12,500 underlying shares at a $31.26 exercise price, expiring October 26, 2027, and 3,777 underlying shares at $60.96, expiring October 30, 2035.
Bio-Techne shareholders approved and adopted the merger agreement for Merck KGaA, Darmstadt, Germany’s proposed acquisition, with 121,929,544 votes for, 1,208,817 against and 30,610 abstentions. Holders of 78.55% of the shares outstanding on August 11, 2026, were present or represented by proxy, constituting a quorum.
The separate non-binding advisory vote on merger-related executive compensation received 25,912,275 votes for, 96,412,306 against and 844,390 abstentions. The Hart-Scott-Rodino waiting period expired September 18, 2026; Bio-Techne expects closing by late 2026 or early 2027, subject to customary closing conditions, including remaining required regulatory approvals. Under the agreement, Merger Sub will merge into Bio-Techne, which will survive as a wholly owned subsidiary of Merck KGaA.
BIO-TECHNE Corp (TECH) reports on shareholder litigation and supplements its proxy disclosures in connection with the proposed merger under which it would become a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany. A special shareholder meeting to vote on the merger is scheduled for September 23, 2026.
The company discloses one lawsuit in Minnesota state court and several shareholder demand letters alleging deficiencies in the proxy statement. While Bio-Techne states it believes these claims are without merit, it is voluntarily providing additional background on sale-process discussions, its engagement of Goldman Sachs, and Goldman’s valuation work, including implied per-share value ranges of $58–$72, $45–$74 and $49–$67 based on different analyses.
Bio-Techne Corporation (TECH) filed its annual report describing a global life-sciences tools and diagnostics business organized into two segments: Protein Sciences (about 72% of fiscal 2026 net sales) and Diagnostics and Spatial Biology (about 28%). Protein Sciences provides reagents and analytical instruments used in research, diagnostics, and cell and gene therapy, while Diagnostics and Spatial Biology supplies in situ hybridization assays, spatial biology platforms, molecular diagnostics kits, and OEM diagnostic controls.
Approximately 48% of sales come from outside the U.S., with a diversified customer base and no single customer above 10% of segment net sales. Bio-Techne continues to grow through acquisitions, including Lunaphore in fiscal 2024 and a staged acquisition of Wilson Wolf by the end of 2027. On June 25, 2026, the company agreed to be acquired by Merck KGaA, Darmstadt, Germany, with each share to be converted at closing into $73.00 in cash, subject to shareholder and regulatory approvals and other customary conditions, with closing expected by late 2026 or early 2027.
Bio-Techne Corporation (TECH) has agreed to be acquired by Merck KGaA, Darmstadt, Germany through a cash merger at $73.00 per share of Bio-Techne common stock. A wholly owned Merck subsidiary will merge into Bio-Techne, which will become a wholly owned subsidiary of Merck and cease to be publicly traded.
At the effective time, each outstanding share (other than specified excluded and dissenting shares) will be converted into the right to receive $73.00 in cash, without interest and subject to tax withholding. Equity awards and ESPP interests will be converted into cash-based awards or settled for cash under detailed formulas.
A special virtual shareholders’ meeting will be held on September 23, 2026. Holders of record at 5:00 p.m. Eastern Time on August 11, 2026 (156,800,296 shares outstanding) may vote, with approval of the merger requiring a majority of the voting power of outstanding shares. The board unanimously determined the merger is in shareholders’ best interests and recommends voting FOR the merger and related proposals. The deal is subject to regulatory approvals; it is not conditioned on financing. Mutual termination fees of $230.455 million (Bio-Techne) and $576.14 million (Parent) may be payable under specified circumstances.
BIO-TECHNE Corp (TECH) reported that officer Shane Bohnen, SVP – General Counsel, received two equity awards on 2026-08-17: 11,344 Restricted Stock Units that vest in three annual installments from 2027–2029, and 18,432 Restricted Stock Units that vest on 2029-08-17. Each unit represents a contingent right to one share of common stock. Bohnen also reports direct holdings of 10,360 common shares and multiple outstanding stock options and performance RSUs with various exercise prices and vesting schedules.
BIO-TECHNE Corp (TECH) reported that its Chief Executive Officer, Kim Kelderman, received equity awards of 57,590 and 93,582 restricted stock units on August 17, 2026. Each unit represents one share of BIO-TECHNE common stock.
The 57,590 RSUs vest in three installments of 19,197, 19,197, and 19,196 units on August 17, 2027, 2028, and 2029. The 93,582 RSUs vest on August 17, 2029. Separately, Kelderman directly holds 82,762 BIO-TECHNE common shares and multiple stock option grants, including options over 115,724 shares at an exercise price of $66.97 expiring August 5, 2027.
BIO-TECHNE Corp (TECH) reported that CFO James Hippel received two equity awards on 2026-08-17: grants of 22,438 Restricted Stock Units and 36,459 Restricted Stock Units, each representing a contingent right to one share of common stock. According to the vesting footnotes, 7,479 RSUs vest on each of 8/17/2027 and 8/17/2028, and 7,480 vest on 8/17/2029 for the first award, while the second award of 36,459 RSUs vests on 8/17/2029. Hippel also holds multiple stock option positions on BIO-TECHNE common stock with exercise prices between $53.60 and $120.46 and expirations from 2027 through 2035, and directly holds 170,183 shares of common stock.
BIO-TECHNE Corp (TECH) director Amy E. Herr reported an indirect grant of 1,381 Restricted Stock Units on 2026-08-17, held through a significant other. Each unit represents a contingent right to receive one share of BIO-TECHNE common stock, vesting in three annual installments in 2027, 2028, and 2029.
The filing also lists existing option and RSU awards with various exercise prices from $53.60 to $120.46 and expiration dates through 2035, along with direct holdings of 2,680 common shares and 576 indirect common shares. No sales or option exercises are reported.